Clinical Trials /

Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC and Other Diseases

NCT03389399

Description:

To estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing brigatinib at 90mg QD.

Related Conditions:
  • Non-Small Cell Lung Carcinoma
Recruiting Status:

Recruiting

Trial Eligibility

Document

Title

  • Brief Title: Pulmonary Physiology and Systemic Inflammatory in EO Pulmonary Events With Brigatinib Use in NSCLC
  • Official Title: Pulmonary Physiology and Systemic Inflammatory Signature Investigations in Early Onset Pulmonary Events Associated With Brigatinib Use in Non-Small Cell Lung Cancer

Clinical Trial IDs

  • ORG STUDY ID: 17-0846.cc
  • NCT ID: NCT03389399

Conditions

  • Non-Small Cell Lung Cancer

Purpose

To estimate the incidence of Early Onset Pulmonary Events (EOPEs), defined as the proportion of participants with a peak reduction in DLCO of 20% or greater after commencing brigatinib at 90mg QD.

Detailed Description

      This is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib
      90 mg QD x 7 days to brigatinib 180 mg QD. Participants who enroll on this study protocol
      will either be taking brigatinib in the context of an ongoing clinical trial, or as part of
      standard of care treatment as licensed by FDA.
    

Trial Arms

NameTypeDescriptionInterventions
Brigatinib 90 mg QD or brigatinib 90 mg QD x 7 daysThis is a single-arm study of patients who plan on starting brigatinib 90 mg QD or brigatinib 90 mg QD x 7 days to brigatinib 180 mg QD. Study procedures include PFTs, 6minute walk test, Modified Borg dyspnea scale (mBDS), and phlebotomy before participants commence brigatinib and on days 2 and 8 of brigatinib treatment. Participants that develop a peak reduction in DLCO of 20% or more from baseline whose DLCO does not return to their baseline level on day 8 may, at the discretion of the investigator, undergo repeated testing on a subsequent time point (e.g., day 15) for serial observation to ensure resolution of EOPE if that is the suspected cause of DLCO reduction.

    Eligibility Criteria

            Inclusion Criteria:
    
              1. Provision to sign and date the consent form, indicating that he or she has been
                 informed of all pertinent aspects of the study, including the potential risks, and is
                 willingly participating.
    
              2. Stated willingness and ability to comply with all scheduled visits and study
                 procedures, and be available for the duration of the study.
    
              3. Be a male or female aged ≥ 18.
    
              4. Must plan on receiving brigatinib at a starting dose of 90 mg QD, regardless of
                 whether they are receiving brigatinib as a part of clinical trial (if they meet
                 eligibility criteria for given clinical trial) or outside of clinical trial as part of
                 standard of care cancer treatment per the FDA license.
    
              5. Have histologically or cytologically confirmed locally advanced or metastatic NSCLC
                 suitable for treatment with brigatinib per either FDA labels, acceptable off label use
                 or within brigatinib clinical trials.
    
              6. Participants must plan on taking Brigatinib as the only systemic cancer treatment.
                 This means that participants cannot be receiving other targeted therapies,
                 chemotherapies, or immunotherapies while on brigatinib (Exceptions:
                 nonimmunosuppressive supportive cancer therapies such as bone targeting agents [e.g.,
                 denosumab], and anti-emetics are allowed).
    
              7. Must have Hemoglobin (Hb) of ≥10 g/dL.
    
              8. Recovered from clinically relevant toxicities (in the opinion of the investigator)
                 related to prior anticancer therapy to National Cancer Institute (NCI) Common
                 Terminology Criteria for Adverse Events (CTCAE, v4.03) grade ≤2.
    
              9. Have Eastern Cooperative Oncology Group (ECOG) performance status ≤2.
    
             10. Must have clearly documented information of previously received systemic cancer
                 treatments including chemotherapy, immunotherapy, small molecule tyrosine-kinase
                 inhibitors (incl. ALK-targeted TKI) and stop date of most recent systemic therapy.
    
            Exclusion Criteria:
    
              1. Have baseline oxygen supplementation requirement (i.e., resting O2 sats on room air ≥
                 90%).
    
              2. Have history or presence of pulmonary interstitial disease or drug-related pneumonitis
                 on CT imaging of chest performed within 28 days prior to starting brigatinib.
    
              3. Have malabsorption syndrome or other GI illness that could affect oral absorption of
                 the study drug in the opinion of the investigator.
    
              4. Have had a blood transfusion within past 120 days.
    
              5. Have received any small molecule inhibitors, including crizotinib, within 7 days of
                 the first dose of Brigatinib (e.g., If first scheduled dose of brigatinib is on a
                 Monday, May 1st, 2017 then last dose of the prior line of small molecule inhibitor
                 must have been given BEFORE Monday, April 24, 2017).
    
              6. Have received cytotoxic chemotherapy, investigational agents, or cytotoxic doses of
                 radiation within 14 days of brigatinib, except SRS or stereotactic body radiosurgery
                 to anatomic sites not involving lung tissue.
    
              7. Have received immunotherapy within 28 days of first dose of brigatinib.
    
              8. Be on corticosteroid within 48 hours prior to first dose of brigatinib.
    
              9. Have uncontrolled, or active cardiac, pulmonary or hematologic disease that can affect
                 interpretation of DLCO, specifically including, but not restricted to: a. Pulmonary
                 interstitial disease or drug-related pneumonitis b. Congestive heart failure (CHF)
                 within 6 months prior to first dose c. Pulmonary embolism within last 6 months
    
             10. Have an ongoing or active infection. The requirement for intravenous (IV) antibiotics
                 is considered active infection.
    
             11. Have a known or suspected hypersensitivity to AP26113 or its excipients.
    
             12. Have any condition or illness that, in the opinion of the investigator, would
                 compromise participant safety or interfere with evaluation of the drug study.
          
    Maximum Eligible Age:100 Years
    Minimum Eligible Age:18 Years
    Eligible Gender:All
    Healthy Volunteers:No

    Primary Outcome Measures

    Measure:To estimate the incidence of Early Onset Pulmonary Events (EOPEs)
    Time Frame:8 days
    Safety Issue:
    Description:EOPEs is defined as the proportion of participants with a peak reduction in Diffusion capacity in the Lung of Carbon monoxide (DLCO) of 20% or greater after commencing brigatinib at 90mg once daily QD.

    Details

    Phase:
    Primary Purpose:Observational
    Overall Status:Recruiting
    Lead Sponsor:University of Colorado, Denver

    Trial Keywords

    • Brigatinib
    • Early Onset Pulmonary Events

    Last Updated